Home/PRM Pharma/Melvin Sharoky, MD

MS

Melvin Sharoky, MD

Head, Corporate and Scientific Affairs

Therapeutic Areas

Cardiovascular Rare Disease Metabolic

PRM Pharma Pipeline

Drug	Indication	Phase
HemiClor (hydrochlorothiazide 6.25 mg)	Hypertension in adults	Approved

Leadership Team at PRM Pharma

Joseph T. McDevitt

President and CEO

Peter R. Kowey, MD

Head, Cardiovascular Products

Deborah Maroko, MD

Head, Medical Affairs

View full PRM Pharma profile